All In Biotech

Drug Trial Radar · NCT00591422

Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas

Phase I Study of Oral Darinaparsin (ZIO-101-C) in Advanced Solid Tumors and Non-Hodgkin's Lymphomas

Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

23

Actual

Start

Aug 2007

Primary completion

Mar 10, 2010

Study completion Mar 10, 2011

Sponsor

Lead sponsor
Alaunos TherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 11, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study of Dariniparsin (ZIO-101-C) in Advanced Solid Tumors and Non-Hodgkin's Lymphomas

Conditions

  • Advanced Cancer

Interventions

  • ZIO-101-C (Darinaparsin)Drug

    Capsule, Dose escalation study from 100 mg to 1000 mg (or Maximum Tolerated Dose). 3 times weekly (\>36 hours between doses) for 3 weeks with 1 week rest.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ToxicitiesTime frame: 6 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Ocoee, Florida

  • Site not named

    Dallas, Texas

  • Site not named

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.